利用创新技术和人工智能识别早产儿视网膜病变的新型生物标志物
本文综述了当前创新技术、人工智能(AI)和预测性生物标志物在早产儿视网膜病变(ROP)诊断与管理中的进展与挑战,涵盖AI检测ROP及其严重程度、进展和治疗反应的模型,OCT与OCTA对亚临床ROP特征的评估,以及减少侵入性操作需求的潜在生物标志物,并强调生物标志物与影像及AI在ROP筛查中的共生整合。
要点
- AI模型可用于检测ROP及其严重程度、进展和治疗反应。
- OCT与OCTA可评估眼底检查常难以察觉的亚临床ROP特征。
- 强调生物标志物与影像及AI在ROP筛查中的共生整合。
核心结论
- 强调在ROP筛查中需将生物学标志物与影像学标志物及AI进行共生整合,以生物标志物在早期疾病检测中的稳健性补充AI算法的预测精度。
研究设计与样本
- 综述,总结当前创新技术、人工智能和预测性生物标志物在ROP诊断与管理中的进展与挑战。
主要发现
- 当前筛查指南仍受检查者间对筛查方式判读差异、部分环境缺乏ROP筛查本地方案、资源匮乏以及更小更年轻婴儿存活率增加等因素限制。
- 综述提供了AI检测ROP及其严重程度、进展和治疗反应的模型概览。
- OCT和OCTA技术可用于评估眼底检查常难以察觉的亚临床ROP特征。
- 探讨了多种潜在生物标志物以减少侵入性操作需求并提高诊断准确性和治疗效果。
临床怎么用
- 原文未据此给出推荐。
局限性
- 当前筛查指南仍受检查者间对筛查方式判读差异的限制。
- 部分环境缺乏ROP筛查本地方案。
- 资源匮乏。
- 更小更年轻婴儿存活率增加带来挑战。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Retinopathy of prematurity (ROP) is a leading cause of preventable vision loss in preterm infants. While appropriate screening is crucial for early identification and treatment of ROP, current screening guidelines remain limited by inter-examiner variability in screening modalities, absence of local protocol for ROP screening in some settings, a paucity of resources and an increased survival of younger and smaller infants. This review summarizes the advancements and challenges of current innovative technologies, artificial intelligence (AI), and predictive biomarkers for the diagnosis and management of ROP. We provide a contemporary overview of AI-based models for detection of ROP, its severity, progression, and response to treatment. To address the transition from experimental settings to real-world clinical practice, challenges to the clinical implementation of AI for ROP are reviewed and potential solutions are proposed. The use of optical coherence tomography (OCT) and OCT angiography (OCTA) technology is also explored, providing evaluation of subclinical ROP characteristics that are often imperceptible on fundus examination. Furthermore, we explore several potential biomarkers to reduce the need for invasive procedures, to enhance diagnostic accuracy and treatment efficacy. Finally, we emphasize the need of a symbiotic integration of biologic and imaging biomarkers and AI in ROP screening, where the robustness of biomarkers in early disease detection is complemented by the predictive precision of AI algorithms.
引用
- Hoyek S, Cruz NFSD, Patel NA, et al. Identification of novel biomarkers for retinopathy of prematurity in preterm infants by use of innovative technologies and artificial intelligence. Prog Retin Eye Res. 2023. PMID: 37611892. doi:10.1016/j.preteyeres.2023.101208
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。